| Name | Title | Contact Details |
|---|---|---|
Jeffrey Chang |
General Counsel | Profile |
Everest Discovery LLC is a WBENC-Certified Woman Business Enterprise, national eDiscovery, Digital Forensics, and Litigation Support provider, headquartered in Philadelphia, PA with additional team members in the central and western states. Our organization has extensive experience supporting the litigation needs of major corporations and law firms. Through leading technology solutions and experienced personnel, Everest is positioned to support our clients across all phases of the Electronic Discovery Reference Model (EDRM). We believe all successful projects require experienced planning, proactive thinking, and outstanding communication. Our core focus is delivering solutions that bring order to chaos and reduce litigation risk through the implementation of proven workflows and leading technologies. Our approach ensures clients have greater control over external spending by promoting cost transparency and predictability, to effectively manage budgeted and forecasted spending. Everests commitment to information security management is reinforced through our organizations ISO 27001:2013 certification.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Arq is a diversified, environmental technology company with products that enable a cleaner and safer planet while actively reducing our environmental impact.
RevGen GENIUS stands as a premier source for aiding businesses in crafting a robust and efficient go-to-market (GTM) strategy. With our expert guidance, clients can drive revenue growth with confidence.